Mobile medical applications increasingly are being used by patients and consumers. Now healthcare providers are evaluating whether and how to work with their patients in tapping these apps. But they're proceeding cautiously because of the dearth of clinical evidence for many consumer apps, and because some developers may be misleading consumers by overstating their products' capabilities.
In September, developers of a consumer-marketed mobile app, UltimEyes, agreed to pay $150,000 to settle an enforcement action by the Federal Trade Commission based on the claim that the app was “scientifically shown to improve vision.” The promoters “did not have the scientific evidence to support their claims,” the FTC said.
Read Full Article »